4572.T

Carna Biosciences, Inc. [4572.T] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

4572.T Stock Summary

4572.T has more than 2 years of cash runway (29 months)

Earnings are expected to fall -100% next year

Profit margins (-1.75%) are lower than the previous year (-0.97%)

Top 10 Correlated ETFs

4572.T

Top 10 Correlated Stocks

4572.T

In the News

4572.T Financial details

Company Rating

Buy

Market Cap

12.63B

Income

-1.85B

Revenue

1.06B

Book val./share

277.65

Cash/share

257.72

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

03 Aug 2023

P/E

-6.33

Forward P/E

PEG

13.95

P/S

11.93

P/B

2.67

P/C

2.88

P/FCF

Quick Ratio

10.48

Current Ratio

12.31

Debt / Equity

0.12

LT Debt / Equity

0.03

EPS (TTM)

-40.19

EPS next Y

EPS next Q

EPS this Y

135.39%

EPS next Y

EPS next 5Y

EPS last 5Y

-4.54%

Revenue last 5Y

12.94%

Revenue Q/Q

-22.04%

EPS Q/Q

SMA20

17.74%

SMA50

58.38%

SMA100

40.39%

Inst Own

Inst Trans

ROA

-37%

ROE

-45%

ROC

-0.39%

Gross Margin

83%

Oper. Margin

-168%

Profit Margin

-175%

Payout

Shs Outstand

17.05M

Shs Float

13.85M

Target Price

52W Range

447.0-984.0

52W High

-24.7%

52W Low

+65.77%

RSI

54.17

Rel Volume

1.06

Avg Volume

832.47K

Volume

882.1K

Perf Week

-3.14%

Perf Month

47.9%

Perf Quarter

-1.07%

Perf Half Y

-5.24%

Beta

1.54584

Volatility

20.2%, 78.72%

Prev Close

-0.94%

Price

741

Change

-8.86%

4572.T Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	77.94	294.51	92.15	158.92	101.84
Net income per share	-125.02	76.05	-90.33	-42.1	-99.1
Operating cash flow per share	-116.49	135.69	-102.53	-121.04	-52.02
Free cash flow per share	-122.52	131.83	-108.12	-124.32	-61.27
Cash per share	139.96	451.31	349.55	300.72	248.14
Book value per share	91.65	353.84	310.92	339.93	267.44
Tangible book value per share	91.65	353.84	310.92	339.93	267.44
Share holders equity per share	91.65	353.84	310.92	339.93	267.44
Interest debt per share	72	67.67	35.54	42.83	22.45
Market cap	8.71B	23.12B	14.91B	13.99B	7.08B
Enterprise value	8.05B	18.93B	11.04B	10.71B	4B
P/E ratio	-7.2	27.91	-13.42	-26.18	-5.25
Price to sales ratio	11.55	7.21	13.15	6.93	5.11
POCF ratio	-7.73	15.65	-11.82	-9.1	-10
PFCF ratio	-7.35	16.1	-11.21	-8.86	-8.49
P/B Ratio	9.82	6	3.9	3.24	1.94
PTB ratio	9.82	6	3.9	3.24	1.94
EV to sales	10.66	5.9	9.74	5.31	2.89
Enterprise value over EBITDA	-6.8	19.43	-10.44	-21.43	-3.22
EV to operating cash flow	-7.13	12.81	-8.75	-6.97	-5.65
EV to free cash flow	-6.78	13.19	-8.3	-6.79	-4.8
Earnings yield	-0.14	0.04	-0.07	-0.04	-0.19
Free cash flow yield	-0.14	0.06	-0.09	-0.11	-0.12
Debt to equity	0.99	0.4	0.26	0.26	0.17
Debt to assets	0.5	0.28	0.21	0.21	0.15
Net debt to EBITDA	0.57	-4.29	3.66	6.56	2.48
Current ratio	4.18	5	6.47	6.87	9.4
Interest coverage	-107.69	119.77	-143.37	-135.32	-239.15
Income quality	0.93	1.62	1.14	2.89	0.54
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.05	-0.03	0.05	0.03	0.18
Capex to revenue	-0.08	-0.01	-0.06	-0.02	-0.09
Capex to depreciation	-4.59	-4.47	-5.55	-2.17	-3.73
Stock based compensation to revenue	0	0.01	0.05	0.03	0.04
Graham number	507.74	778.14	794.95	567.44	772.24
ROIC	1.22	-0.2	0.28	0.24	0.52
Return on tangible assets	-0.68	0.15	-0.23	-0.1	-0.32
Graham Net	54.53	316.02	271.57	217.09	206.63
Working capital	1.27B	4.22B	3.98B	4.54B	3.67B
Tangible asset value	887.45M	3.85B	3.82B	4.31B	3.64B
Net current asset value	788.95M	3.75B	3.7B	4.2B	3.48B
Invested capital	0.77	0.19	0.11	0.13	0.08
Average receivables	0	0	0	0	0
Average payables	1.75M	1.83M	2.35M	1.91M	2.13M
Average inventory	114.37M	105.1M	101.97M	107.51M	114.51M
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0.7	5.58	2.88	6.18	4.17
Days of inventory on hand	161.29	174.8	198.55	297.87	252.19
Receivables turnover	0	0	0	0	0
Payables turnover	524.47	65.42	126.66	59.02	87.44
Inventory turnover	2.26	2.09	1.84	1.23	1.45
ROE	-1.36	0.21	-0.29	-0.12	-0.37
Capex per share	-6.02	-3.86	-5.6	-3.28	-9.25

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q1

Metric	2022-03-31	2022-06-30	2022-09-30	2022-12-31	2023-03-31
Revenue per share	41.23	2.71	2.43	0	14.33
Net income per share	-1.12	-3.27	-4.14	0	-32.78
Operating cash flow per share	0	0	0	0	0
Free cash flow per share	0	0	0	0	0
Cash per share	362.63	44.52	35.43	0	257.72
Book value per share	337.57	42.07	37.48	0	277.65
Tangible book value per share	337.57	42.07	37.48	0	277.65
Share holders equity per share	337.57	42.07	37.48	0	277.65
Interest debt per share	34.76	3.87	3.17	0	16.24
Market cap	14.1B	94.69B	89.96B	0	7.52B
Enterprise value	9.68B	90.42B	86.56B	-3.08B	3.7B
P/E ratio	-233.33	-68.82	-51.57	0	-3.62
Price to sales ratio	25.42	332.39	351.32	0	33.15
POCF ratio	0	0	0	0	0
PFCF ratio	0	0	0	0	0
P/B Ratio	3.1	21.4	22.81	0	1.71
PTB ratio	3.1	21.4	22.81	0	1.71
EV to sales	17.46	317.37	338.06	-10.57	16.29
Enterprise value over EBITDA	2.25K	-293.87	-202.3	5.66	-7.22
EV to operating cash flow	0	0	0	0	0
EV to free cash flow	0	0	0	0	0
Earnings yield	0	0	0	0	-0.07
Free cash flow yield	0	0	0	0	0
Debt to equity	0.18	0.18	0.15	0.17	0.12
Debt to assets	0.15	0.15	0.13	0.15	0.11
Net debt to EBITDA	-1.02K	13.91	7.94	5.66	7.47
Current ratio	10.49	10.43	11.8	9.4	12.31
Interest coverage	8.94	-219.14	-363.53	-500.18	-564.5
Income quality	0	0	0	0	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	92.35	55.63	59.12	0	452.53
ROIC	0	0.08	0.15	0.21	0.16
Return on tangible assets	0	-0.07	-0.1	-0.13	-0.11
Graham Net	306.26	37.53	30.24	0	227.47
Working capital	4.75B	4.57B	4B	3.67B	4.41B
Tangible asset value	4.54B	4.42B	3.94B	3.64B	4.4B
Net current asset value	4.44B	4.27B	3.76B	3.48B	4.25B
Invested capital	0.1	0.09	0.08	0.08	0.06
Average receivables	0	0	0	0	0
Average payables	1.57M	665K	1.86M	2.6M	2M
Average inventory	111.47M	112.82M	114.93M	117.6M	127.69M
Days sales outstanding	0	0	0	0	0
Days payables outstanding	1.8	1.06	7.19	3.69	3.76
Days of inventory on hand	238.23	250.92	258.65	222.82	253.22
Receivables turnover	0	0	0	0	0
Payables turnover	49.98	84.57	12.53	24.4	23.96
Inventory turnover	0.38	0.36	0.35	0.4	0.36
ROE	0	-0.08	-0.11	-0.15	-0.12
Capex per share	0	0	0	0	0

4572.T Frequently Asked Questions

What is Carna Biosciences, Inc. stock symbol ?

Carna Biosciences, Inc. is a JP stock and trading under the symbol 4572.T

What is Carna Biosciences, Inc. stock quote today ?

Carna Biosciences, Inc. stock price is $741 today.

Is Carna Biosciences, Inc. stock public?

Yes, Carna Biosciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 832.47K
Market Capitalization 12.63B
Employee 65
CEO Dr. Kohichiro Yoshino Ph.D.
Headquarters Kobe,JP
IPO Date 2008-03-25
Website https://www.carnabio.com

Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, kinase protein assay kits, and stable cell lines, as well as biotinylated kinases to use in the study of kinase-molecule interactions. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection and interaction, live-cell kinase assay, ClariCELL kinase cell-based assay, crystallization, weak affinity chromatography, and tyrosine kinase cell-based assay services, as well as custom production of ultra-pure proteins for crystallography. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable small molecule inhibitor of CDC7 kinase that is in preclinical trials to treat cancer; AS-0871, a small molecule drug for inflammatory and immune disorders, which is in Phase 1 clinical trials; and AS-1763, an orally bioavailable and non-covalent inhibitor for the treatment of chronic lymphocytic leukemia and other B cell malignancies that is in preclinical trials. The company has collaborations with Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals. Carna Biosciences, Inc. was founded in 2003 and is based in Kobe, Japan.